A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

BACKGROUND: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor subsets most amenable to angiogenesis modulation are lacking. METHODS: We prof...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Pentheroudakis, George, Kotoula, Vassiliki, Fountzilas, Elena, Kouvatseas, George, Basdanis, George, Xanthakis, Ioannis, Makatsoris, Thomas, Charalambous, Elpida, Papamichael, Demetris, Samantas, Epaminontas, Papakostas, Pavlos, Bafaloukos, Dimitrios, Razis, Evangelia, Christodoulou, Christos, Varthalitis, Ioannis, Pavlidis, Nicholas, Fountzilas, George
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3933361/
https://ncbi.nlm.nih.gov/pubmed/24555920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-111
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky